Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.70%
#2 Ontology Gas Ontology Gas +17.76%
#3 GoPlus Security GoPlus Security +9.80%
#4 Janction Janction +9.64%
#5 DMT-NAT DMT-NAT +7.80%
#6 Provenance Blockchain Provenance Blockchain +6.63%
#7 B3 (Base) B3 (Base) +6.09%
#8 Ontology Ontology +6.08%
#9 Status Status +5.87%
#10 Everything Everything +5.64%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
PJSC Pharmsynthez PJSC Pharmsynthez

PJSC Pharmsynthez

LIFE
Rank in Stocks #34086
PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation,... PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation, production, and supply of both proprietary (officinal) and generic active pharmaceutical ingredients across Russia and the Commonwealth of Independent States (CIS). Its portfolio of branded medicines includes Neovir, Segidrin, Fenasid, and Penkrofton, which are employed in critical therapeutic areas such as oncology, gynecology, the management of immune deficiencies, and tuberculosis. Public Joint-Stock Company Pharmsynthez has also established a collaboration with HiFiBiO Therapeutics Inks for the clinical advancement and market introduction of their SARS-CoV-2 neutralizing antibody within Russia. The company, which began operations in 1996, is headquartered in St. Petersburg, Russia.
Share Price
$0.02082992
Last synced: 2026-08-14
Market Cap
$6.27M
Change (1 day)
-3.31%
Change (1 year)
-51.62%
Country
RU
Trade PJSC Pharmsynthez (LIFE)

Category

Healthcare
Revenue for PJSC Pharmsynthez (LIFE)
Revenue in Aug 2026 TTM: 0
According to PJSC Pharmsynthez latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for PJSC Pharmsynthez from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE